ClinicalTrials.gg
TerminatedNCT02087085BEACONUpdated Apr 23, 2019Results posted

A Safety and Efficacy Study of Brimonidine Intravitreal Implant in Geographic Atrophy Secondary to Age-related Macular Degeneration

A Phase 2 interventional study of 400 µg Brimonidine Implant and Sham in Geographic Atrophy and Macular Degeneration, sponsored by Allergan. Terminated at 41 sites in 6 countries. Open to participants aged 55 Years and older. Per ClinicalTrials.gov, last updated 2019-04-23.

Sponsored by Allergan (part of AbbVie) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
310
Allocation
Randomized
Ages
55 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 131 studies in Geographic Atrophy with a site in United States — 35 open to participants now, 45 under way, 5 of them phase 3. Geographic Atrophy · United States.

Enrollment
22nd of 107
310 · median 98
Started
2014
with 5 others
Phase 2
43 of 131
11 open now
Registered
32nd of 131
by date

Among the 131 studies in Geographic Atrophy with a site in United States, this one is the 22nd largest by enrollment of the 107 interventional ones that give a count, is one of 6 that started in 2014, is one of 43 in phase 2, and was the 32nd registered.

Geographic Atrophy

188 studies on the registry are indexed under Geographic Atrophy; 52 are open to participants now.

Browse Geographic Atrophy studies →

Open to participants now

35 of the 131 studies in Geographic Atrophy with a site in United States are open now. Recruiting first, the newest first:

30 more — sign in →

All 35 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 40 Geographic Atrophy studies recruiting now, 31 (78%) set no upper age limit and none (0%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.

This study: 55 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 131 studies in Geographic Atrophy with a site in United States, or all of them as a file.
02

Study summary

This study will assess the safety and efficacy of the brimonidine intravitreal implant in participants with geographic atrophy due to age-related macular degeneration.

03

Conditions studied

  • Geographic Atrophy
  • Macular Degeneration
04

Who can participate

Ages eligible
55 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Geographic atrophy due to age-related macular degeneration in the study eye
  • Visual acuity better than or equal to 20/125 Snellen equivalent in the study eye and 20/200 Snellen equivalent in the fellow eye.

Exclusion criteria

Exclusion Criteria:

  • Cataract surgery or Laser-Assisted in situ Keratomileusis (LASIK) in the study eye in the last 3 months
  • Infections in either eye in the last 3 months
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
310 participants (actual)

Study arms

  • Experimental
    400 µg Brimonidine Implant

    400 µg brimonidine implant in the study eye, administered by intravitreal injections using the Brimonidine Drug Delivery System (Brimo DDS®) applicator every 3 months from Baseline (Day 1) through Month 21.

    Drug: 400 µg Brimonidine Implant

  • Sham comparator
    Sham

    Sham treatment (control) in the study eye, administered by intravitreal injections using a needleless drug delivery system (DDS) applicator every 3 months from Baseline (Day 1) through Month 21.

    Other: Sham

Interventions

  • 400 µg brimonidine implant in the study eye using Brimo DDS® applicator on Day 1, and every 3 months through Month 21.

    Also known as: AGN-190342

  • OtherSham

    Sham treatment with needleless applicator (no implant) to the study eye on Day 1, and every 3 months through Month 21.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Geographic Atrophy (GA) Lesion Area of the Study Eye as Assessed by Fundus Autofluorescence (FAF) at Month 24

    GA lesion area was measured in mm\^2 by FAF in the study eye and was quantified by the central reading center. The study eye was defined as the eye that met inclusion/exclusion criteria with the worst standard Best Correct Visual Acuity (BCVA). If the BCVA in both eyes was similar the right eye was selected as the study eye. A positive change from baseline indicates an increase in size of GA lesion area (worsening; disease progression). Mixed model for repeated measures (MMRM) was used for analysis.

    Time frame: Baseline (Day 1) to Month 24

Secondary outcomes

  1. Change From Baseline in Standard Best Corrected Visual Acuity (BCVA) Score as Assessed by Early Treatment Diabetic Retinopathy Study (ETDRS) Chart at Month 24

    BCVA was measured using an eye chart (ETDRS) and was reported as the number of letters read correctly (ranging from 0 to 100 letters) in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). The study eye was defined as the eye that met inclusion/exclusion criteria with the worst standard BCVA. If the BCVA in both eyes was similar the right eye was selected as the study eye. A positive change from baseline indicates an improvement and a negative change from baseline indicates a worsening. MMRM was used for analysis.

    Time frame: Baseline (Day 1) to Month 24

  2. Change From Baseline in Low Luminance BCVA Score as Assessed by ETDRS Chart at Month 24

    Low Luminance BCVA was measured by placing a 2.0 log unit neutral density filter over the best correction for that eye and having the participant read the normally illuminated ETDRS chart and was reported as the number of letters read correctly (ranging from 0 to 100 letters) in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). The study eye was defined as the eye that met inclusion/exclusion criteria with the worst standard BCVA. If the BCVA in both eyes was similar the right eye was selected as the study eye. A positive change from baseline indicates an improvement and a negative change from baseline indicates a worsening. MMRM was used for analysis.

    Time frame: Baseline (Day 1) to Month 24

Other outcomes

  1. Change From Baseline in Retinal Sensitivity in the Study Eye

    Time frame: Baseline (Day 1) to Month 24

07

Results

Posted Apr 23, 2019

Participant flow

Participant flow — Overall Study
Milestone400 µg Brimonidine ImplantSham
Started154156
Completed3440
Not completed120116
Withdrew: Adverse event1014
Withdrew: Lack of efficacy43
Withdrew: Lost to follow-up64
Withdrew: Withdrawal by subject911
Withdrew: Protocol violation10
Withdrew: Study terminated by sponsor8780
Withdrew: Other miscellaneous reasons34

Outcome measures

PrimaryChange From Baseline in Geographic Atrophy (GA) Lesion Area of the Study Eye as Assessed by Fundus Autofluorescence (FAF) at Month 24

GA lesion area was measured in mm\^2 by FAF in the study eye and was quantified by the central reading center. The study eye was defined as the eye that met inclusion/exclusion criteria with the worst standard Best Correct Visual Acuity (BCVA). If the BCVA in both eyes was similar the right eye was selected as the study eye. A positive change from baseline indicates an increase in size of GA lesion area (worsening; disease progression). Mixed model for repeated measures (MMRM) was used for analysis.

Time frame:
Baseline (Day 1) to Month 24
Reported as:
Least squares mean · mm^2
Change From Baseline in Geographic Atrophy (GA) Lesion Area of the Study Eye as Assessed by Fundus Autofluorescence (FAF) at Month 24
mm^2400 µg Brimonidine ImplantSham
Change From Baseline in Geographic Atrophy (GA) Lesion Area of the Study Eye as Assessed by Fundus Autofluorescence (FAF) at Month 243.1455 ± 0.13773.5044 ± 0.1359
Statistical analysis
  • 400 µg Brimonidine Implant vs Sham · MMRM · p = 0.047 (MMRM model included treatment group, study region, analysis visit and treatment-by-visit interaction as factors and baseline value and baseline value-by-analysis visit interaction as covariates.) · Least squares mean difference: -0.3589 · 95% CI -0.7132 to -0.0047
SecondaryChange From Baseline in Standard Best Corrected Visual Acuity (BCVA) Score as Assessed by Early Treatment Diabetic Retinopathy Study (ETDRS) Chart at Month 24

BCVA was measured using an eye chart (ETDRS) and was reported as the number of letters read correctly (ranging from 0 to 100 letters) in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). The study eye was defined as the eye that met inclusion/exclusion criteria with the worst standard BCVA. If the BCVA in both eyes was similar the right eye was selected as the study eye. A positive change from baseline indicates an improvement and a negative change from baseline indicates a worsening. MMRM was used for analysis.

Time frame:
Baseline (Day 1) to Month 24
Reported as:
Least squares mean · letters read correctly
Change From Baseline in Standard Best Corrected Visual Acuity (BCVA) Score as Assessed by Early Treatment Diabetic Retinopathy Study (ETDRS) Chart at Month 24
letters read correctly400 µg Brimonidine ImplantSham
Change From Baseline in Standard Best Corrected Visual Acuity (BCVA) Score as Assessed by Early Treatment Diabetic Retinopathy Study (ETDRS) Chart at Month 24-10.9 ± 1.0-9.7 ± 1.0
Statistical analysis
  • 400 µg Brimonidine Implant vs Sham · MMRM · p = 0.390 (MMRM model included treatment group, study region, analysis visit and treatment-by-visit interaction as factors and baseline value and baseline value-by-analysis visit interaction as covariates.) · Least squares mean difference: -1.2 · 95% CI -3.9 to 1.5
SecondaryChange From Baseline in Low Luminance BCVA Score as Assessed by ETDRS Chart at Month 24

Low Luminance BCVA was measured by placing a 2.0 log unit neutral density filter over the best correction for that eye and having the participant read the normally illuminated ETDRS chart and was reported as the number of letters read correctly (ranging from 0 to 100 letters) in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). The study eye was defined as the eye that met inclusion/exclusion criteria with the worst standard BCVA. If the BCVA in both eyes was similar the right eye was selected as the study eye. A positive change from baseline indicates an improvement and a negative change from baseline indicates a worsening. MMRM was used for analysis.

Time frame:
Baseline (Day 1) to Month 24
Reported as:
Least squares mean · letters read correctly
Change From Baseline in Low Luminance BCVA Score as Assessed by ETDRS Chart at Month 24
letters read correctly400 µg Brimonidine ImplantSham
Change From Baseline in Low Luminance BCVA Score as Assessed by ETDRS Chart at Month 24-8.1 ± 1.0-6.7 ± 1.0
Statistical analysis
  • 400 µg Brimonidine Implant vs Sham · MMRM · p = 0.301 (MMRM model included treatment group, study region, analysis visit and treatment-by-visit interaction as factors and baseline value and baseline value-by-analysis visit interaction as covariates.) · Least squares mean difference: -1.4 · 95% CI -4.2 to 1.3
Other pre-specifiedChange From Baseline in Retinal Sensitivity in the Study Eye
Time frame:
Baseline (Day 1) to Month 24

Results for this outcome have not been posted.

Adverse events

Collected over From first dose of study drug to date of last visit (up to approximately 33 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
400 µg Brimonidine Implant5/154 (3.2%)48/154 (31.2%)79/154 (51.3%)
Sham6/156 (3.8%)37/156 (23.7%)61/156 (39.1%)
Most frequent serious events
Showing 10 of 118
Most frequent serious events
Event400 µg Brimonidine ImplantSham
Acute myocardial infarctionCardiac disorders3/1540/156
Atrial fibrillationCardiac disorders3/1541/156
BradycardiaCardiac disorders3/1540/156
Cardiac failure congestiveCardiac disorders3/1541/156
PneumoniaInfections and infestations3/1543/156
Coronary artery diseaseCardiac disorders2/1541/156
Sinus node dysfunctionCardiac disorders2/1540/156
Visual acuity reducedEye disorders2/1540/156
Vitreous haemorrhageEye disorders2/1540/156
FallInjury, poisoning and procedural complications2/1542/156
Most frequent other events
Showing 10 of 12
Most frequent other events
Event400 µg Brimonidine ImplantSham
Vitreous floatersEye disorders29/1541/156
Conjunctival haemorrhageEye disorders21/15411/156
Urinary tract infectionInfections and infestations3/15415/156
Visual impairmentEye disorders12/1546/156
NasopharyngitisInfections and infestations12/15412/156
Eye painEye disorders11/1549/156
HypertensionVascular disorders8/15411/156
FallInjury, poisoning and procedural complications5/15410/156
Visual acuity reducedEye disorders9/1546/156
Dry eyeEye disorders8/1546/156

Baseline characteristics

All randomized participants.

Age, Continuous
Age, Continuous(years)400 µg Brimonidine ImplantShamTotal
Mean76.9 ± 7.8977.0 ± 7.2476.9 ± 7.56
Sex: Female, Male
Sex: Female, Male(Participants)400 µg Brimonidine ImplantShamTotal
Female10191192
Male5365118
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)400 µg Brimonidine ImplantShamTotal
White153156309
Black or African American101
Geographic Atrophy (GA) Lesion Area by Fundus Autofluorescence (FAF)
Geographic Atrophy (GA) Lesion Area by Fundus Autofluorescence (FAF)(millimeters squared (mm^2))400 µg Brimonidine ImplantShamTotal
Mean5.1611 ± 3.70165.4761 ± 3.59615.3212 ± 3.6457
08

Study locations

41 sites
  • Retinal Consultants of Arizona, Ltd., Retinal Research Institute
    Phoenix, Arizona 85014, United States
  • Associated Retina Consultants
    Phoenix, Arizona 85020, United States
  • University of California, San Diego, Jacobs Retina Center, Shiley Eye Center
    La Jolla, California 92037, United States
  • Northern California Retina Vitreous Associates
    Mountain View, California 94040, United States
  • Retina Consultants of Southern Colorado, PC
    Colorado Springs, Colorado 80909, United States
  • "National Ophthalmic Research Institute Retina Consultants of Southwest Florida"
    Fort Myers, Florida 33912, United States
  • Retina Specialty Institute
    Pensacola, Florida 32503, United States
  • Retina Vitreous Associates of Florida
    Saint Petersburg, Florida 33711, United States
  • Southern Vitreoretinal Associates, PL
    Tallahassee, Florida 32308, United States
  • Center for Retina and Macular Disease
    Winter Haven, Florida 33880, United States
  • Georgia Retina
    Decatur, Georgia 30030, United States
  • Raj K. Maturi, MD
    Indianapolis, Indiana 46290, United States
  • Retina Associates of Western New York
    Rochester, New York 14620, United States
  • Charlotte Eye Ear Nose & Throat Associates, PA
    Charlotte, North Carolina 28210, United States
  • Oregon Retina, LLP
    Eugene, Oregon 97401, United States
  • Casey Eye Institute, Oregon Health and Science University
    Portland, Oregon 97239, United States
  • Mid Atlantic Retina, Wills Eye Retina Surgeons
    Philadelphia, Pennsylvania 19107, United States
  • Retina Research Institute of Texas
    Abilene, Texas 79606, United States
  • Texas Retina Associates
    Arlington, Texas 76012, United States
  • "Austin Retina Associates "
    Austin, Texas 78705, United States
  • Retina Foundation of the Southwest
    Dallas, Texas 75231, United States
  • Valley Retina Institute
    McAllen, Texas 78503, United States
  • Strategic Clinical Research Group, LLC
    Willow Park, Texas 76087, United States
  • Center for Eye Research Australia
    Melbourne, Victoria 3002, Australia
  • Lions Eye Institute, University of Western Australia
    Nedlands, 6009, Australia
  • Service d'Ophtalmologie
    Bordeaux, 33076, France
  • "Centre Hospitalier Intercommunal de Creteil "
    Creteil, 94000, France
  • "Universitat Bonn, Abteilung fur Augenheilkunde "
    Bonn, 53127, Germany
  • STZ Eyetrial
    Tübingen, 72076, Germany
  • Università di Cagliari (presidio San Giovanni di Dio)
    Bologna, 40138, Italy
  • Università di Cagliari (presidio San Giovanni di Dio)
    Cagliari, 09124, Italy
  • Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico
    Milano, 20122, Italy
  • IRCCS Ospedale San Raffaele
    Milano, 20132, Italy
  • "Dir IV Clinica Oculistica di Milano, Ospedale Generale ""Luigi Sacco"" "
    Milano, 20157, Italy
  • Universita degli Studi di Padova, Dipartimento di Neuroscienze
    Padova, 35128, Italy
  • Universita degli Studi di Torino
    Torino, 10122, Italy
  • Clinical Research Unit, Level2, Bristol Eye Hospital, Lower Maudlin Street
    Bristol, BS1 2LX, United Kingdom
  • Frimley Park Hospital, Eye clinical trials Unit, Department of Opthalmology
    Camberley, GU16 7UJ, United Kingdom
  • Moorfields Eye Hospital
    London, EC1V 2PD, United Kingdom
  • Macular Unit, Hospital of St Cross
    Rugby, CV22 5PX, United Kingdom
  • Royal Hallamshire Hospital, Eye Department
    Sheffield, S10 2JF, United Kingdom
09

References and documents

Publications

  • Miere A, Capuano V, Kessler A, Zambrowski O, Jung C, Colantuono D, Pallone C, Semoun O, Petit E, Souied E. Deep learning-based classification of retinal atrophy using fundus autofluorescence imaging. Comput Biol Med. 2021 Mar;130:104198. doi: 10.1016/j.compbiomed.2020.104198. Epub 2020 Dec 28. PubMed 33383315 ↗
  • Kuppermann BD, Patel SS, Boyer DS, Augustin AJ, Freeman WR, Kerr KJ, Guo Q, Schneider S, Lopez FJ; Brimo DDS Gen 1 Study Group. PHASE 2 STUDY OF THE SAFETY AND EFFICACY OF BRIMONIDINE DRUG DELIVERY SYSTEM (BRIMO DDS) GENERATION 1 IN PATIENTS WITH GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION. Retina. 2021 Jan 1;41(1):144-155. doi: 10.1097/IAE.0000000000002789. PubMed 32134802 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2014 to primary completion in Mar 2018, 46 months.

Results were first posted in Apr 2019, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 12, 2014
First posted
Mar 14, 2014
StartActual
May 9, 2014
Primary completionActual
Mar 30, 2018
CompletionActual
Mar 30, 2018
Results first posted
Apr 23, 2019
Last update
Apr 23, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 23, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02087085
Lead sponsor
Allergan
Responsible party
Sponsor
First posted
Mar 14, 2014
Start date
May 9, 2014
Primary completion
Mar 30, 2018
Completion
Mar 30, 2018
Results posted
Apr 23, 2019
Last update
Apr 23, 2019

Study contacts

Claire Winterson
study director · Allergan

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brimonidine

Start the discussion